 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...167168169170171172173174175176177...208209» |
- ||||| AiTan (rivoceranib) / HLB Bio Group, gefitinib / Generic mfg.
Clinical: #ESMO20 Treatment naive EGFR+ mNSCLC randomized to oral apatinib 500mg qday or placebo, both with gefitinib 250mg qday. Stratified by mutation, sex, PS. Primary endpoint PFS. #LCSM @OncoAlert (Twitter) - Sep 20, 2020
- |||||| AiTan (rivoceranib) / HLB Bio Group, erlotinib / Generic mfg., gefitinib / Generic mfg.
Clinical: #ESMO20 Results from the randomized, double blind ACTIVE trial (CTONG 1706) of apatinib + gefitinib (vs placebo + gefitinib) as 1L treatment for #EGFR mutant NSCLC. Apatinib is a VEGFR2 TKI. Inevitable parallels to RELAY (erlotinib + ramucirumab). #LCSM @OncoAlert (Twitter) - Sep 20, 2020
- |||||| AiTan (rivoceranib) / HLB Bio Group, gefitinib / Generic mfg.
Biomarker: Fantastic overview of EGFRi + VEGFi in #EGFR+ #lungcancer by @LeciaSequist . Role of VEGF still unclear. Interesting find in apatinib + gefitinib that TP53 biomarker may show benefit & eval could be applied to other data sets. #LCSM #ESMO20 #OncoAlert @EGFRResisters (Twitter) - Sep 20, 2020
- |||| AiTan (rivoceranib) / HLB Bio Group
EGFRi + VEGFi in #NSCLC discussed by my friend @LeciaSequist > Erl + Ram, and Bev available options that include VEGFi in @NCCN > PFS benefit consistently seen in trials > Apatinib is VEGFr TKI modest benefit, sign' diarrhea > Osi + Bev did not seem > than Osi @myESMO #ESMO20 (Twitter) - Sep 20, 2020
- |||| AiTan (rivoceranib) / HLB Bio Group, gefitinib / Generic mfg.
Clinical: We are now going to hear on Apatinib + Gefitinib in #EGFR MT NSCLC and Osi + Bev in EGFR T790M pts @myESMO #ESMO20. Await a discussion by @LeciaSequist, coming up shortly! #LCSM @EGFRResisters (Twitter) - Sep 20, 2020
- | AiTan (rivoceranib) / HLB Bio Group
Preclinical, Journal, Combination therapy, IO Biomarker: Synergistic anti-tumour effects of Clostridium butyricum in combination with apatinib in CT26 colorectal tumour-bearing mice. (Pubmed Central) - Sep 19, 2020
Our study confirms that C. butyricum combined with apatinib in the treatment of xenografted colon tumour in mice can significantly inhibit tumour growth and promote cell apoptosis than apatinib alone treatments, providing the reference for clinical treatments.
- ||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, Platinum resistant: Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer (clinicaltrials.gov) - Sep 19, 2020
P=N/A, N=40, Recruiting, Sponsor: Qianfoshan Hospital
Our study confirms that C. butyricum combined with apatinib in the treatment of xenografted colon tumour in mice can significantly inhibit tumour growth and promote cell apoptosis than apatinib alone treatments, providing the reference for clinical treatments. Not yet recruiting --> Recruiting
- || AiRuiKa (camrelizumab) / Incyte
Clinical, Journal, Mismatch Repair, Microsatellite Instability: Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial. (Pubmed Central) - Sep 18, 2020
Not yet recruiting --> Recruiting Camrelizumab provided durable objective response and disease control in pre-treated patients with dMMR/MSI-H advanced or metastatic solid tumour, being a promising treatment option for these patients.
- |||||| AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Enrollment open, Trial completion date, Trial primary completion date: A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 17, 2020
P3, N=600, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Camrelizumab provided durable objective response and disease control in pre-treated patients with dMMR/MSI-H advanced or metastatic solid tumour, being a promising treatment option for these patients. Not yet recruiting --> Recruiting | Trial completion date: Aug 2022 --> Dec 2022 | Trial primary completion date: Jan 2022 --> May 2022
- ||| SHR7280 / Jiangsu Hengrui Pharma
New P1 trial: The PK/PD Study of SHR7280 Tablets in Healthy Subjects. (clinicaltrials.gov) - Sep 17, 2020
P1, N=98, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P2 trial: A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Sep 16, 2020
P2, N=50, Not yet recruiting, Sponsor: Shandong Cancer Hospital and Institute
- || ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma
Enrollment open, Trial initiation date: Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment (clinicaltrials.gov) - Sep 15, 2020
P1, N=24, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting | Trial completion date: Aug 2022 --> Dec 2022 | Trial primary completion date: Jan 2022 --> May 2022 Not yet recruiting --> Recruiting | Initiation date: Apr 2020 --> Aug 2020
- ||| ropivacaine liposomal sustained release (HR18034) / Jiangsu Hengrui Pharma
New P1 trial: A Trial of HR18034 in Inguinal Hernia Repair (clinicaltrials.gov) - Sep 15, 2020
P1, N=64, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||||| AiTan (rivoceranib) / HLB Bio Group
Enrollment open, Trial initiation date: FZPL-?-302: A Study of Fluzoparib (clinicaltrials.gov) - Sep 14, 2020
P3, N=680, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting | Initiation date: Apr 2020 --> Aug 2020 Not yet recruiting --> Recruiting | Initiation date: Feb 2020 --> Jun 2020
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, PD(L)-1 Biomarker, IO biomarker, Platinum resistant: Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - Sep 13, 2020
P2, N=27, Not yet recruiting, Sponsor: Sun Yat-sen University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, PD(L)-1 Biomarker, IO biomarker: Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - Sep 13, 2020
P2, N=25, Not yet recruiting, Sponsor: Sun Yat-sen University
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Phase I trial of Apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma () - Sep 13, 2020 - Abstract #ASTRO2020ASTRO_1663;
Not yet recruiting --> Recruiting | Initiation date: Feb 2020 --> Jun 2020 Embargoed Information
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] To Explore the Imaging Parameter to Predict Antiangiogenic Adverse Events in Normal Organs (Science Center, Quick Pitch Sessions) - Sep 13, 2020 - Abstract #ASTRO2020ASTRO_1472;
Embargoed Information Pretreatment lower 18F-RGD SUVmax of the liver, spleen, and cardia were related to fatigue, hypertension, and nausea during apatinib treatment, respectively.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Safety and Efficacy of PD-1 Antibody SHR-1210 Combined with Concurrent Chemoradiotherapy to Treat Locally Advanced Esophageal Squamous Cell Carcinoma: a Phase Ib Clinical Trial (Science Center, Oral Scientific Sessions) - Sep 13, 2020 - Abstract #ASTRO2020ASTRO_1389;
P=N/A
The results from our original phase Ib clinical trial revealed that dCCRT combined with SHR-1210 exhibited a remarkable therapeutic effect with tolerable toxicity, which would provide a new strategy for LAESCC. Phase III clinical trial is ongoing to confirmed the present results.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] A Phase II Trial of Radiotherapy Concurrent with Apatinib in Locally Advanced Bone and Soft Tissue Sarcoma of the Head and Neck: the Preliminary Results (Science Center, Quick Pitch Sessions) - Sep 13, 2020 - Abstract #ASTRO2020ASTRO_636;
IMRT concurrent with apatinib shows promising efficacy in patients with locally advanced bone and soft tissue sarcoma of the head and neck. Further randomized controlled trial is warranted.
- || AiTan (rivoceranib) / HLB Bio Group, vinorelbine tartrate / Generic mfg.
Clinical, Journal: Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial. (Pubmed Central) - Sep 13, 2020
P2
This regimen may have potential as a treatment option for patients with wild-type advanced NSCLC whose disease failed at least 2 prior lines of chemotherapy. ClinicalTrials.gov Identifier: NCT03652857.
- ||||| plinabulin (BPI 2358) / BeyondSpring
Breakthrough therapy designation: .@BlayneyDouglas, of @StanfordMed, discusses the FDA's breakthrough therapy designation to plinabulin for chemotherapy-induced neutropenia. https://t.co/1ZkHEOUerf (Twitter) - Sep 12, 2020
- ||| perfluorohexyloctane (NOV03) / Novaliq, Bausch Health
#Novaliq Gmbh has had medical devices (NovaTears,EvoTears eye drops) manufactured by non-compliant companies. In the factory of horrors Miteni Spa, workers forced to work without ..... Read on here https://t.co/Ff7z6we1KW (copy & past if doesn't redirect) #Ursapharm (Twitter) - Sep 12, 2020
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Analysis of metabolome changes in the HepG2 cells of apatinib treatment by using the NMR-based metabolomics. (Pubmed Central) - Sep 9, 2020
The differential metabolites which were identified from the reconstructed OPLS-DA loading plots also reflected in these disturbed metabolic pathways. Our works could allow us to well understand the therapeutic effect of apatinib, especially in metabolism.
- | pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine
Journal: Pyrotinib combined with CDK4/6 inhibitor in HER2-positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients. (Pubmed Central) - Sep 9, 2020
P1
Our works could allow us to well understand the therapeutic effect of apatinib, especially in metabolism. This translational study suggests that pyrotinib combined with SHR6390 may serve as a promising strategy for patients with HER2-positive GC.
- |||| NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
Trial completion date, Trial primary completion date: Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study) (clinicaltrials.gov) - Sep 9, 2020
P3, N=560, Recruiting, Sponsor: Bausch Health Americas, Inc.
This translational study suggests that pyrotinib combined with SHR6390 may serve as a promising strategy for patients with HER2-positive GC. Trial completion date: Oct 2020 --> Apr 2021 | Trial primary completion date: Aug 2020 --> Apr 2021
- || dexmedetomidine nasal spray / Jiangsu Hengrui Pharma
Trial completion: A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Children (clinicaltrials.gov) - Sep 9, 2020
P1, N=48, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Trial completion date: Oct 2020 --> Apr 2021 | Trial primary completion date: Aug 2020 --> Apr 2021 Recruiting --> Completed
- | AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, Trial initiation date, Trial primary completion date: Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Sep 8, 2020
P=N/A, N=150, Not yet recruiting, Sponsor: Sun Yat-sen University
Recruiting --> Completed Trial completion date: Jul 2025 --> Oct 2025 | Initiation date: Jul 2020 --> Oct 2020 | Trial primary completion date: Jul 2023 --> Oct 2023
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment change: Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer (clinicaltrials.gov) - Sep 8, 2020
P1/2, N=30, Recruiting, Sponsor: Wuhan Union Hospital, China
Trial completion date: Jul 2025 --> Oct 2025 | Initiation date: Jul 2020 --> Oct 2020 | Trial primary completion date: Jul 2023 --> Oct 2023 N=50 --> 30
- | Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
Phase classification, Trial initiation date, Minimal residual disease: Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL (clinicaltrials.gov) - Sep 8, 2020
P3, N=28, Recruiting, Sponsor: Zhongda Hospital
N=50 --> 30 Phase classification: P4 --> P3 | Initiation date: Jul 2020 --> Mar 2020
- |||| dexmedetomidine nasal spray / Jiangsu Hengrui Pharma
Enrollment open: A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Adults (clinicaltrials.gov) - Sep 8, 2020
P2/3, N=108, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Phase classification: P4 --> P3 | Initiation date: Jul 2020 --> Mar 2020 Not yet recruiting --> Recruiting
- ||| plinabulin (BPI 2358) / BeyondSpring
Breakthrough therapy designation: $BYSI Receives Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia Indication (Twitter) - Sep 8, 2020
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer (clinicaltrials.gov) - Sep 7, 2020
P2, N=23, Not yet recruiting, Sponsor: Sun Yat-sen University
- || perfluorohexyloctane (NOV03) / Novaliq, Bausch Health
Review, Journal: Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy. (Pubmed Central) - Sep 5, 2020
The use of either CF or standard silicone oil appears reasonable for most patients with RD associated with PVR. Heavy silicone oil, which is not available for routine clinical use in the USA, may not demonstrate evidence of superiority over standard silicone oil.
- | perfluorohexyloctane (NOV03) / Novaliq, Bausch Health
Journal: A Review on Evidence-Based Treatments for Meibomian Gland Dysfunction. (Pubmed Central) - Sep 4, 2020
All eight forms of treatments, including self-applied eyelid warming, thermal pulsation, IPL, MG probing, antibiotics, lipid-containing eye drops, and perfluorohexyloctane, were effective against MGD, although with varying extent of clinical improvements. A better understanding on the mechanisms of actions may guide physicians to make better treatment decisions targeting the root causes.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab combined with apatinib for refractory gestational trophoblastic neoplasia: A phase 2, single-arm, prospective Study () - Sep 3, 2020 - Abstract #IGCS2020IGCS_453;
The combination of camrelizumab and apatinib demonstrated tolerable toxicity and showed encouraging activity in patients with refractory GTN. Larger clinical trials of predictive biomarkers of response are needed.
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: YOUNGBC-11: First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients (clinicaltrials.gov) - Sep 2, 2020
P2, N=90, Recruiting, Sponsor: Fudan University
- |||| otesaconazole (VT-1161) / Mycovia Pharma
Enrollment closed, Trial completion date, Trial primary completion date: ultraVIOLET: Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections (clinicaltrials.gov) - Sep 2, 2020
P3, N=180, Active, not recruiting, Sponsor: Mycovia Pharmaceuticals Inc.
Larger clinical trials of predictive biomarkers of response are needed. Recruiting --> Active, not recruiting | Trial completion date: Jul 2020 --> Nov 2020 | Trial primary completion date: Jul 2020 --> Nov 2020
- | AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P2 trial, Metastases: Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Sep 1, 2020
P2, N=37, Not yet recruiting, Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New P4 trial: Impact of Remimazolam on Prognosis After Bladder Cancer Surgery (clinicaltrials.gov) - Aug 30, 2020
P4, N=1128, Not yet recruiting, Sponsor: Peking University First Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: A Phase ? Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Aug 30, 2020
P2, N=42, Not yet recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University
- || AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Trial primary completion date: A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Aug 29, 2020
P2, N=132, Recruiting, Sponsor: Reistone Biopharma Company Limited
Recruiting --> Active, not recruiting | Trial completion date: Jul 2020 --> Nov 2020 | Trial primary completion date: Jul 2020 --> Nov 2020 Trial primary completion date: Jul 2020 --> Dec 2020
- || pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine
Clinical, Journal: HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib. (Pubmed Central) - Aug 28, 2020
Our findings reveal that HER2 exon 20 insertion mutations were detected in a small subset of lung adenocarcinomas. Given the different drug sensitivities, determining the mutation subtype by next-generation sequencing at the time of diagnosis might make sense.
- || AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Trial completion date, Trial primary completion date: AMBER2: A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis. (clinicaltrials.gov) - Aug 27, 2020
P2, N=152, Recruiting, Sponsor: Reistone Biopharma Company Limited
Given the different drug sensitivities, determining the mutation subtype by next-generation sequencing at the time of diagnosis might make sense. Trial completion date: Sep 2020 --> Mar 2021 | Trial primary completion date: Jul 2020 --> Mar 2021
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC (clinicaltrials.gov) - Aug 27, 2020
P2, N=30, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Enrollment closed, Trial completion date, Trial primary completion date: A Trial of SHR6390 in Healthy Caucasian Volunteers (clinicaltrials.gov) - Aug 27, 2020
P1, N=36, Active, not recruiting, Sponsor: Atridia Pty Ltd.
Trial completion date: Sep 2020 --> Mar 2021 | Trial primary completion date: Jul 2020 --> Mar 2021 Recruiting --> Active, not recruiting | Trial completion date: Sep 2021 --> Sep 2020 | Trial primary completion date: Mar 2021 --> May 2020
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] A randomized multicentered phase III study to evaluate apatinib in subjects with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (On-Demand) - Aug 27, 2020 - Abstract #ESMO2020ESMO_3498;
P3
Funding: Jiangsu Hengrui Medicine, China. Clinical trial identification: NCT03048877.
- AiTan (rivoceranib) / HLB Bio Group, gefitinib / Generic mfg.
[VIRTUAL] ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): A multicentered, randomized, double-blind, placebo-controlled phase III trial (CTONG1706) (Channel 1) - Aug 27, 2020 - Abstract #ESMO2020ESMO_3419;
P3
Funding: The 5010 Clinical Research Foundation of Sun Yat-sen University; Jiangsu Hengrui Medicine Co., Ltd. Clinical trial identification: NCT02824458.
- || AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, Trial primary completion date: Neo-PLANET: Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach Adenocarcinoma (clinicaltrials.gov) - Aug 25, 2020
P2, N=36, Recruiting, Sponsor: Shanghai Zhongshan Hospital
Clinical trial identification: NCT02824458. Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2019 --> Dec 2020
- ||| AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
New P1 trial: A Bioequivalence Study to Compare Two Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects (clinicaltrials.gov) - Aug 25, 2020
P1, N=130, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.